Natco Pharma stock corrected sharply due to weak Q3 results, but future opportunities like semaglutide offer hope.

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

Lupin and Natco receive US FDA approval for generic Tracleer tablets for oral suspension: Our Bureau, Mumbai Monday, February 10, 2025, 15:45 Hrs [IST] Global pharma major Lupin L ...

Hyderabad: NATCO Pharma Limited has announced final approval of its Abbreviated New Drug Application (ANDA) for Bosentan ...

Several companies, including Oil India, HAL, Bharat Forge, Gillette India, KPI Green Energy, and Procter & Gamble Health, ...

Find all the latest Q3 results 2025 updates for TVS Srichakra, Rail Vikas Nigam, Shriram Properties, Ashok Leyland, Saint ...

In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.Natco Pharma is also ...

In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...

Natco Pharma plans to launch its CTPR products very shortly, which is estimated to have a market size of over ₹2,000 crore in India. Natco Pharma shares surged after the drug maker unveiled the first ...